ReviewMolecular cancer2021
mRNA in cancer immunotherapy: beyond a source of antigen.
Review in Molecular cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 77 citations in OpenAlex.
- Endogenous targeting lipid nanoparticles for systemic mRNA delivery to lung cancer tumors.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Review
- Immunotherapy in Melanoma: A Dynamic Frontier in Cancer Treatment : Author List.Current treatment options in oncology · 2026Review
- Article
- mRNA-LNP vaccination orchestrates systemic immunity to control human papillomavirus-positive head and neck squamous cell carcinoma.Molecular therapy. Nucleic acids · 2025Article
- Nucleic acid-encoded antibody gene transfer-next generation of antibody therapies.Drug delivery · 2025Review
- mRNA vaccines and SiRNAs targeting cancer immunotherapy: challenges and opportunities.Discover oncology · 2025Review
- Pharmaceutical perspectives on oligonucleotide therapeutics and delivery systems.Pharmacological reviews · 2025Review
- Endo/Lysosomal-Escapable Lipid Nanoparticle Platforms for Enhancing mRNA Delivery in Cancer Therapy.Pharmaceutics · 2025Review
- mRNA vaccines in the context of cancer treatment: from concept to application.Journal of translational medicine · 2025Review
- Recent Advances and Prospects in RNA Drug Development.International journal of molecular sciences · 2024Review
- Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.Signal transduction and targeted therapy · 2024Review
- Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology.Precision clinical medicine · 2024Review
- Advances in Nonviral mRNA Delivery Materials and Their Application as Vaccines for Melanoma Therapy.ACS applied bio materials · 2024Review
- mRNA vaccine development and applications: A special focus on tumors (Review).International journal of oncology · 2024Review
- From structural design to delivery: mRNA therapeutics for cancer immunotherapy.Exploration (Beijing, China) · 2024Review
- Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery.Nanomedicine : nanotechnology, biology, and medicine · 2024Review
- An in vitro-transcribed circular RNA targets the mitochondrial inner membrane cardiolipin to ablate EIF4G2Nature cancer · 2024Article
- The advances of adjuvants in mRNA vaccines.NPJ vaccines · 2023Review
- Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
mRNA therapeutics have become the focus of molecular medicine research. Various mRNA applications have reached major milestones at high speed in the immuno-oncology field. This can be attributed to the knowledge that mRNA is one of nature's core building blocks carrying important information and can be considered as a powerful vector for delivery of therapeutic proteins to the patient.For a long time, the major focus in the use of in vitro transcribed mRNA was on development of cancer vaccines, using mRNA encoding tumor antigens to modify dendritic cells ex vivo. However, the versatility of mRNA and its many advantages have paved the path beyond this application. In addition, due to smart design of both the structural properties of the mRNA molecule as well as pharmaceutical formulations that improve its in vivo stability and selective targeting, the therapeutic potential of mRNA can be considered as endless.As a consequence, many novel immunotherapeutic strategies focus on the use of mRNA beyond its use as the source of tumor antigens. This review aims to summarize the state-of-the-art on these applications and to provide a rationale for their clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.